NCT01717157 - A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Healthy

Interventions

DRUG

Treatment A: DUROGESIC (8.4 mg fentanyl)

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

DRUG

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

DRUG

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

DRUG

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

DRUG

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Trial Locations (1)

Antwerp

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY